PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26348533-1	2016	AIMS: Olodaterol, a novel beta2-adrenergic receptor agonist, is a long-acting, once-daily inhaled bronchodilator approved for the treatment of chronic obstructive pulmonary disease.	olodaterol	6-16	adrenoceptor beta 2	Homo sapiens	26-51	
30311516-2	2018	Olodaterol 5 microg, a long-acting beta2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy.	olodaterol	0-10	adrenoceptor beta 2	Homo sapiens	35-53	
28810065-3	2017	The aim of our study was to explore the anti-fibrotic activity of the long-acting beta2 -adrenoceptor agonist olodaterol in primary human lung fibroblasts (HLF) and in murine models of pulmonary fibrosis.	olodaterol	110-120	adrenoceptor beta 2	Homo sapiens	82-101	
26676161-1	2015	Olodaterol (BI 1744 CL) is a novel, once-daily long-acting beta2-agonist (LABA) designed with the aim of improving beta2-adrenoreceptor selectivity and intrinsic activity.	olodaterol	0-10	adrenoceptor beta 2	Homo sapiens	115-135	
24705868-5	2014	beta2-Adrenoceptor mRNA was increased by about 100 % after 1 h exposure to formoterol or olodaterol but decreased by about 60 % after 4 h agonist exposure.	olodaterol	89-99	adrenoceptor beta 2	Homo sapiens	0-18	
25824824-10	2015	The long-acting beta2 -adrenoceptor agonist olodaterol attenuated pulmonary inflammation through mechanisms that are separate from direct inhibition of bronchoconstriction.	olodaterol	44-54	adrenoceptor beta 2	Homo sapiens	16-35	
25781609-4	2015	The aim of our study was to test the efficacy of the long-acting beta2-AR agonist olodaterol with regard to its antitussive property in a pre-clinical model of citric acid-induced cough in guinea pigs and to compare the results to different clinically relevant beta2-AR agonists.	olodaterol	82-92	adrenoceptor beta 2	Homo sapiens	65-73	
25781609-4	2015	The aim of our study was to test the efficacy of the long-acting beta2-AR agonist olodaterol with regard to its antitussive property in a pre-clinical model of citric acid-induced cough in guinea pigs and to compare the results to different clinically relevant beta2-AR agonists.	olodaterol	82-92	adrenoceptor beta 2	Homo sapiens	261-269	
25824824-0	2015	The long-acting beta2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.	olodaterol	44-54	adrenoceptor beta 2	Homo sapiens	16-35	
25824824-3	2015	The aim of our study was to determine the efficacy of the long-acting beta2 -adrenoceptor agonist olodaterol to inhibit pulmonary inflammation and to elucidate mechanism(s) underlying its anti-inflammatory actions.	olodaterol	98-108	adrenoceptor beta 2	Homo sapiens	70-89	
25773742-1	2015	Olodaterol (Striverdi( ) Respimat( )) is an inhaled long-acting beta2-adrenoceptor agonist (LABA) indicated as a once-daily maintenance bronchodilator therapy in adults with COPD.	olodaterol	0-10	adrenoceptor beta 2	Homo sapiens	64-82	
24158691-1	2013	Olodaterol (Striverdi( ) Respimat( )) is a novel, long-acting, beta2-adrenergic receptor agonist developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD).	olodaterol	0-10	adrenoceptor beta 2	Homo sapiens	63-88	
22796455-7	2012	The beta(2)-adrenoceptor agonist olodaterol caused a reduction of ppET-1 mRNA by 45%.	olodaterol	33-43	adrenoceptor beta 2	Homo sapiens	4-24	
22483689-3	2012	KEY FINDINGS: ET-1 caused a marked and rapid in onset (1 hr) increase in beta(2)-adrenoceptor mRNA, an effect additive to that of short time (1 hr) exposure to the beta(2)-adrenoceptor agonist olodaterol.	olodaterol	193-203	adrenoceptor beta 2	Homo sapiens	73-93	
22483689-3	2012	KEY FINDINGS: ET-1 caused a marked and rapid in onset (1 hr) increase in beta(2)-adrenoceptor mRNA, an effect additive to that of short time (1 hr) exposure to the beta(2)-adrenoceptor agonist olodaterol.	olodaterol	193-203	adrenoceptor beta 2	Homo sapiens	164-184	
20096576-0	2010	Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.	olodaterol	13-23	adrenoceptor beta 2	Homo sapiens	41-59	
21839850-2	2011	Olodaterol is a novel long-acting beta(2)-adrenoceptor agonist with a pre-clinical profile that suggests 24-h bronchodilation may be achieved with once-daily administration.	olodaterol	0-10	adrenoceptor beta 2	Homo sapiens	34-54	
21839850-13	2011	CONCLUSIONS: Olodaterol appears to be a promising long-acting beta(2)-adrenoceptor agonist,with bronchodilation maintained over 24 h that offers an opportunity for once-daily dosing in patients who require maintenance bronchodilator therapy for the management of COPD symptoms.	olodaterol	13-23	adrenoceptor beta 2	Homo sapiens	62-82	
21357659-8	2011	The tight binding of olodaterol to the human beta(2)-AR and stabilization of the ternary complex were confirmed in functional experiments monitoring adenylyl cyclase activity after extensive washout.	olodaterol	21-31	adrenoceptor beta 2	Homo sapiens	45-55	
21357659-9	2011	Taken together, binding, kinetic, and functional data support the existence of a stable complex with the beta(2)-AR that, with a dissociation half-life >17 h, might indeed be a rationale for the 24-h duration of action of olodaterol.	olodaterol	225-235	adrenoceptor beta 2	Homo sapiens	105-115	
20371707-0	2010	Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.	olodaterol	36-46	adrenoceptor beta 2	Homo sapiens	64-82	
31425937-1	2019	The term ultra-LABA indicates once-daily beta2-AR agonists (abediterol, indacaterol, olodaterol and vilanterol) that are single enantiomers of the (R)-configuration.	olodaterol	85-95	adrenoceptor beta 2	Homo sapiens	41-49	
33622325-4	2021	OBJECTIVE: We hypothesize that the LABA olodaterol can inhibit airway inflammation resulting from exposure to respiratory syncytial virus (RSV) via its binding receptor, the beta2-adrenergic receptor.	olodaterol	40-50	adrenoceptor beta 2	Homo sapiens	174-199	
33622325-10	2021	Gene silencing of the beta2-adrenergic receptor in NCI-H292 negated the ability of olodaterol to inhibit IL-8 secretion from both RSV infection and lipopolysaccharide stimulus, as did blocking of the receptor with ICI 118,551 and butaxamine.	olodaterol	83-93	adrenoceptor beta 2	Homo sapiens	22-47	
33622325-11	2021	CONCLUSIONS: Olodaterol exhibits inherent anti-inflammatory properties on the airway epithelium, in addition to its bronchodilation properties, that is mediated through the beta2-adrenergic receptor and independent of ICS usage.	olodaterol	13-23	adrenoceptor beta 2	Homo sapiens	173-198